2020 ASCO Virtual Direct™ Highlights
Playback speed
10 seconds
2020 ASCO Update on HER2+ MBC: Tucatinib vs. TD-M1 vs. Neratinib - Which Recently FDA Approved Agent Is the Best Option for Sequencing With Existing Therapies?
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Reshma L. Mahtani
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Reshma L. Mahtani
180 views
July 13, 2020
Comments 0
Login to view comments.
Click here to Login
Breast